Hard Lessons Jean Hynes: Dig Deep and Hold Your Position
Feb 12, 2026
Jean Hynes, CEO of Wellington Management and former biotech analyst, shares career-defining, research-driven investing calls. She discusses dissecting drug pipelines, navigating patent cliffs and market structure, and the crisis around a blockbuster drug that plunged 90% overnight. She also reflects on leadership lessons and how she’s positioning a large asset manager for the future.
AI Snips
Chapters
Transcript
Episode notes
Patent Erosion Got Much Faster
- Patent losses accelerated as retail consolidation and PBMs made generic switches happen in about a year instead of five.
- That change forced high-margin drugmakers to either rapidly find new launches or face steep, fast revenue declines.
Model Management Decisions Not Just Sales
- Do model management incentives and likely strategic moves when forecasting earnings, not just product uptake.
- Hynes missed that new CEO Fred Hassan would cut the dividend and lower near-term earnings to reinvest in the Zetia launch.
Swapping Into The Acquirer
- After Schering Plough was acquired by Merck in March 2009, Jean sold Schering Plough and bought Merck to capture the value from the transaction.
- The deal included stock consideration, so retaining Schering Plough would have missed further upside as Merck recovered.